{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:32Z","timestamp":1761710132668,"version":"3.32.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neuropharm.2024.110246","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:33:37Z","timestamp":1733333617000},"page":"110246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Modeling of Parkinson's disease by intrastriatal administration of streptozotocin"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0470-0819","authenticated-orcid":false,"given":"Jelena","family":"Osmanovic Barilar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Papic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Rubic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrik","family":"Meglic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-2555","authenticated-orcid":false,"given":"Robert","family":"Bagaric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Babic Perhoc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-7107","authenticated-orcid":false,"given":"Davor","family":"Virag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Homolak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1865-7142","authenticated-orcid":false,"given":"Melita","family":"Salkovic-Petrisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-2034","authenticated-orcid":false,"given":"Ana","family":"Knezovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110246_bib1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.neuropharm.2009.01.005","article-title":"A study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia","volume":"56","author":"Agrawal","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110246_bib2","article-title":"Antidiabetic drugs in Parkinson's disease","volume":"11","author":"Aguirre-Vidal","year":"2024","journal-title":"Clin. Parkinson. Relat. Disorder."},{"key":"10.1016\/j.neuropharm.2024.110246_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102200","article-title":"The classical and non-classical axes of renin-angiotensin system in Parkinson disease: the bright and dark side of the moon","volume":"94","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2024.110246_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102209","article-title":"New insight on the possible role of statins in Vascular Parkinsonism: a need for presumptive therapy","volume":"95","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2024.110246_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18495","article-title":"The potential role of brain renin-angiotensin system in the neuropathology of Parkinson disease: friend, foe or turncoat?","volume":"28","author":"Al-Qahtani","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2024.110246_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-023-04771-7","article-title":"Metformin role in Parkinson's disease: a double-sword effect","volume":"479","author":"Alrouji","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2024.110246_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.661973","article-title":"Where dopaminergic and cholinergic systems interact: a gateway for tuning neurodegenerative disorders","volume":"15","author":"Amalric","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson's disease: a new target for disease modification?","volume":"145\u2013146","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.110246_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2018.12.018","article-title":"Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice","volume":"148","author":"Babic Perhoc","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110246_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ame2.12209","article-title":"Animal models in the study of Alzheimer's disease and Parkinson's disease: a historical perspective","volume":"5","author":"Banerjee","year":"2022","journal-title":"Anim. Model. Experimen. Med."},{"key":"10.1016\/j.neuropharm.2024.110246_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00702-020-02152-8","article-title":"Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease","volume":"127","author":"Barilar","year":"2020","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110246_bib12","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/nprot.2006.205","article-title":"Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study \u201crecognition memory.\u201d","volume":"1","author":"Bevins","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2024.110246_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/JAD-161289","article-title":"Intracerebroventricular streptozotocin induces obesity and dementia in lewis rats","volume":"60","author":"Bloch","year":"2017","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2024.110246_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2024.110246_bib15","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/febs.15908","article-title":"Interpreting the role of the striatum during multiple phases of motor learning","volume":"289","author":"Cataldi","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2024.110246_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/1567205011310040006","article-title":"Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease","volume":"10","author":"Correia","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2024.110246_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.112964","article-title":"Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced \u03b1-synucleinopathy","volume":"320","author":"Crabb\u00e9","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110246_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.110672","article-title":"Glucose metabolism impairment in Parkinson's disease","volume":"199","author":"Dai","year":"2023","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2024.110246_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40035-023-00368-8","article-title":"Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions","volume":"12","author":"Dovonou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuropharm.2024.110246_bib20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1471-4159.2006.04368.x","article-title":"Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein","volume":"101","author":"Gr\u00fcnblatt","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2024.110246_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JPD-181305","article-title":"High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson's disease","volume":"8","author":"Hogg","year":"2018","journal-title":"JPD"},{"key":"10.1016\/j.neuropharm.2024.110246_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110246_bib23","doi-asserted-by":"crossref","first-page":"R169","DOI":"10.1530\/EC-19-0348","article-title":"Imaging of brain glucose uptake by PET in obesity and cognitive dysfunction: life-course perspective","volume":"8","author":"Iozzo","year":"2019","journal-title":"Endocrine Connec."},{"key":"10.1016\/j.neuropharm.2024.110246_bib24","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: a new treatment in Parkinson's disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib25","doi-asserted-by":"crossref","first-page":"9088","DOI":"10.3390\/ijms24109088","article-title":"Parkinson's disease: exploring different animal model systems","volume":"24","author":"Khan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s12035-022-03188-5","article-title":"From determining brain insulin resistance in a sporadic Alzheimer's disease model to exploring the region-dependent effect of intranasal insulin","volume":"60","author":"Knezovic","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2024.110246_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2018.02.027","article-title":"Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease","volume":"135","author":"Knezovic","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2024.110246_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-015-1394-4","article-title":"Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease","volume":"122","author":"Knezovic","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110246_bib29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00702-015-1394-4","article-title":"Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease","volume":"122","author":"Knezovic","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110246_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-2006-9102","article-title":"Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease","volume":"9","author":"Lester-Coll","year":"2006","journal-title":"J. Alzheim. Dis. : JAD"},{"key":"10.1016\/j.neuropharm.2024.110246_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1515\/revneuro-2022-0093","article-title":"Recent research progress on metabolic syndrome and risk of Parkinson's disease","volume":"34","author":"Li","year":"2023","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/02611929231157756","article-title":"Poor translatability of biomedical research using animals - a narrative review","volume":"51","author":"Marshall","year":"2023","journal-title":"Altern. Lab. Anim. : ATLA"},{"key":"10.1016\/j.neuropharm.2024.110246_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bph.14846","article-title":"Evidence for central antispastic effect of botulinum toxin type A","volume":"177","author":"Matak","year":"2020","journal-title":"Br. J. Pharmacol."},{"author":"Megli\u0107","key":"10.1016\/j.neuropharm.2024.110246_bib34"},{"key":"10.1016\/j.neuropharm.2024.110246_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2967\/jnumed.116.183152","article-title":"Metabolic imaging in Parkinson disease","volume":"58","author":"Meles","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.neuropharm.2024.110246_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101234","article-title":"The brain as an insulin-sensitive metabolic organ","volume":"52","author":"Milstein","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.neuropharm.2024.110246_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4161\/spmg.1.2.16606","article-title":"Enhanced chemiluminescence (ECL) for routine immunoblotting","volume":"1","author":"Mruk","year":"2011","journal-title":"Spermatogenesis"},{"key":"10.1016\/j.neuropharm.2024.110246_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00213","article-title":"Neurodegenerative diseases \u2013 is metabolic deficiency the root cause?","volume":"14","author":"Muddapu","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2022.114174","article-title":"PET imaging in animal models of Parkinson's disease","volume":"438","author":"Ni","year":"2023","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2024.110246_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2024.110246_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/biom13030518","article-title":"Actions and consequences of insulin in the striatum","volume":"13","author":"Patel","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2024.110246_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-4328(98)00158-2","article-title":"Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v, injection of streptozotocin: a correlation analysis","volume":"102","author":"Prickaerts","year":"1999","journal-title":"Behav. Brain Res."},{"year":"2022","series-title":"Applying an OMICs Approach to Investigate the Effects of Citrus and Cucumber Supplementation on Broiler Chickens under Control and Escherichia coli LPS Challenge Conditions (PhD)","author":"Riva","key":"10.1016\/j.neuropharm.2024.110246_bib43"},{"key":"10.1016\/j.neuropharm.2024.110246_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/nu15163585","article-title":"The molecular mechanisms of the relationship between insulin resistance and Parkinson's disease pathogenesis","volume":"15","author":"Ruiz-Pozo","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2024.110246_bib45","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00702-011-0651-4","article-title":"Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study","volume":"118","author":"Salkovic-Petrisic","year":"2011","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2024.110246_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2023.1248727","article-title":"New insights in animal models of neurotoxicity-induced neurodegeneration","volume":"17","author":"Sanfeliu","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2024.110246_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135754","article-title":"Therapies modulating insulin resistance in Parkinson's disease: a cross talk","volume":"749","author":"Sharma","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2024.110246_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.12.002","article-title":"Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents","volume":"33","author":"Shonesy","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2024.110246_bib49","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1038\/ncomms9543","article-title":"Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward","volume":"6","author":"Stouffer","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2024.110246_bib50","doi-asserted-by":"crossref","first-page":"537","DOI":"10.33549\/physiolres.930111","article-title":"The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas","volume":"50","author":"Szkudelski","year":"2001","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2024.110246_bib51","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JAD-143222","article-title":"Characterization of cerebral damage in a monkey model of Alzheimer's disease induced by intracerebroventricular injection of streptozotocin","volume":"46","author":"Yeo","year":"2015","journal-title":"J. Alzheim. Dis."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:07:04Z","timestamp":1736197624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":51,"alternative-id":["S0028390824004155"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110246","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling of Parkinson's disease by intrastriatal administration of streptozotocin","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110246"}}